Antidiabetics/Selected Ophthalmic Non-Cardioselective Beta-Blockers Interactions

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Moderate. These medicines may cause some risk when taken together. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

Beta-blockers may decrease the symptoms of low blood sugar. Beta-blockers may also lower your blood sugar.

What might happen:

If your blood sugar becomes too low, the beta-blocker may hide the symptoms. Sweating that occurs with low blood sugar is not hidden by the beta-blockers.

What you should do about this interaction:

When you are taking these medicines together, you should check your blood sugar level carefully. Be aware that symptoms of low blood sugar may be hidden by your beta-blockers, except for sweating.Your healthcare professionals (e.g. doctor or pharmacist) may already be aware of this interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

  • 1.Popp DA, Shah SD, Cryer PE. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin- dependent diabetes mellitus. J Clin Invest 1982 Feb;69(2):315-26.
  • 2.Hansten PD. Drug interactions update. Beta-blocking agents and antidiabetic drugs. Drug Intell Clin Pharm 1980 Jan;14:46-50.
  • 3.Lithell H, Pollare T, Vessby B. Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Press 1992 Aug;1(2):92-101.
  • 4.Kovacic D, Marinsek M, Gobec L, Lainscak M, Podbregar M. Effect of selective and non-selective beta-blockers on body weight, insulin resistance and leptin concentration in chronic heart failure. Clin Res Cardiol 2008 Jan;97(1):24-31.
  • 5.Silverstone BZ, Marcus T. Hypoglycemia due to ophthalmic timolol in a diabetic. Harefuah 1990 Jun 15;118(12):693-4.
  • 6.Velde TM, Kaiser FE. Ophthalmic timolol treatment causing altered hypoglycemic response in a diabetic patient. Arch Intern Med 1983 Aug; 143(8):1627.
  • 7.Angelo-Nielsen K. Timolol topically and diabetes mellitus. JAMA 1980 Nov 21;244(20):2263.
  • 8.Uusitalo H, Nino J, Tahvanainen K, Turjanmaa V, Ropo A, Tuominen J, Kahonen M. Efficacy and systemic side-effects of topical 0.
  • 9% timolol aqueous solution and 0.
  • 10% timolol hydrogel. Acta Ophthalmol Scand 2005 Dec;83(6):723-8.
  • 11.Korte JM, Kaila T, Saari KM. Systemic bioavailability and cardiopulmonary effects of 0.
  • 12% timolol eyedrops. Graefes Arch Clin Exp Ophthalmol 2002 Jun;240(6):430-5.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, except as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.